ClinicalTrials.gg
TerminatedNCT06441682ReALiSeUpdated Sep 15, 2026

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2 interventional study of ARGX-119 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by argenx. Terminated at 9 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated following review of interim data indicating that continuation was unlikely to demonstrate a clinically meaningful treatment effect. The decision was made to minimize unnecessary participant burden.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Enrollment
44th of 72
60 · median 75
Started
2024
with 8 others
Phase 2
21 of 82
2 open now
Registered
70th of 82
by date

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 44th largest by enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 21 in phase 2, and was the 70th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period when all participants will receive the same dose of ARGX-119. Participation in the study will last up to approximately 100 weeks.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is at least 18 and ≤80 years of age
  • The participant is diagnosed with familial or sporadic ALS according to Gold Coast criteria
  • The participant has a Treatment Research Initiative to Cure ALS (TRICALS) risk profile of ≥ -6.0 to \< -2.0
  • Slow vital capacity (SVC) of ≥ 60% of the predicted value according to Global Lung Function Initiative 2012

Exclusion criteria

Exclusion Criteria:

  • Use of noninvasive ventilation more than 10 hours a day or use of a tracheostomy for ventilatory support
  • Any history of or current exposure to any gene or cell therapies (off-label use or ) for ALS
  • Pregnant or lactating state or intention to become pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ARGX-119 - Dose 1

    Participants will receive first dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period

    Biological: ARGX-119

  • Experimental
    ARGX-119 - Dose 2

    Participants will receive second dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period

    Biological: ARGX-119

  • Experimental
    ARGX-119 - Dose 3

    Participants will receive third dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period

    Biological: ARGX-119

  • Placebo comparator
    Placebo

    Participants will receive placebo intravenously during the double-blinded treatment period followed by ARGX-119 in active treatment extension period

    Biological: ARGX-119 · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of adverse events (AEs)

    Time frame: Up to week 96

Secondary outcomes

  1. Rate of change from baseline in electrophysiological muscle scan (MScan)-derived motor unit number (MUN)

    Time frame: Up to week 24

  2. Maximum observed serum concentration (Cmax) of ARGX-119

    Time frame: Up to week 96

  3. Incidence of anti-drug antibodies (ADA) against ARGX-119 in serum over time

    Time frame: Up to week 96

  4. Prevalence of anti-drug antibodies (ADA) against ARGX-119 in serum over time

    Time frame: Up to week 96

07

Study locations

9 sites
  • UZ Leuven
    Leuven, 3000, Belgium
  • Kaye Edmonton Clinic
    Edmonton, 11400, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, H3A 2B4, Canada
  • Aarhus Universitets Hospital
    Aarhus, 8200, Denmark
  • Bispebjerg University Hospital
    Copenhagen, 2400, Denmark
  • Hôpital La Pitié Salpêtrière
    Paris, 75013, France
  • CHU Bretonneau
    Tours, 37000, France
  • UMC Utrecht
    Utrecht, 3584 CX, Netherlands
  • Akademiskt specialistcentrum Karolinska Institutet
    Stockholm, 113 61, Sweden
08

References and documents

Publications

  • Moss KR, Darvishi FB, Badawi Y, Fish LA, Funke JR, Pedersen TH, Robitaille R, Arnold WD, Burgess RW, Meriney SD, Nishimune H, Saxena S. The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease. J Neurosci. 2025 Nov 12;45(46):e1353252025. doi: 10.1523/JNEUROSCI.1353-25.2025. PubMed 41224659 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Aug 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Oct 23, 2024
Primary completionActual
Aug 12, 2026
CompletionActual
Aug 12, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441682
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Oct 23, 2024
Primary completion
Aug 12, 2026
Completion
Aug 12, 2026
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adimanebart · Anti-MuSK Agonistic Monoclonal Antibody ARGX-119

Start the discussion